v3.24.2
Financing (Tables)
 6 Months Ended
Jun. 28, 2024
Debt Disclosure [Abstract]  
Components of Debt The components of the Company’s debt were as follows ($ in millions):
Outstanding Amount
Description and Aggregate Principal AmountJune 28, 2024December 31, 2023
Euro-denominated commercial paper (€929 million)(e)
$995 $1,026 
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)(f)
— 993 
2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma Notes”)(b)
700 699 
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(f)
499 499 
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(b)
1,336 1,376 
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(f)
855 881 
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d)
191 218 
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(a)
641 660 
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(b)
1,333 1,374 
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)(c)
236 252 
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”)(b)
797 797 
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(f)
857 883 
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)(b)
1,866 1,923 
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(d)
329 376 
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)(b)
1,325 1,365 
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”)(b)
891 891 
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(f)
499 499 
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)(b)
795 819 
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”)(b)
890 890 
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(f)
982 981 
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(f)
985 984 
Other8 16 
Total debt17,010 18,402 
Less: currently payable(701)(1,695)
Long-term debt$16,309 $16,707 
(a) Issued by DH Europe Finance S.A. (“Danaher International”).
(b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”).
(c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”).
(d) Issued by DH Japan Finance S.A. (“Danaher Japan”).
(e) Issued by Danaher Corporation or Danaher International II.
(f) Issued by Danaher Corporation.